Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral sulopenem etzadroxil/probenecid in uUTI
NCT05584657Phase 3Completed
- Sponsor
- Iterum Therapeutics plc
- Start
- Oct 2022
- Primary completion
- Nov 2023
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sulopenem etzadroxil in urinary tract infection (UTI), sponsored by Iterum Therapeutics plc. Started Oct 2022; status: completed.
02
Drugs
sulopenem etzadroxil
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on NCT05584657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05584657.